Class summary at a glance.

Every drug in the Lipid-based Polyene Antifungal class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $3.7Mcombined across class
Total Rx claims: 2K488 unique beneficiaries
Generic mfrs (active): 5across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Amphotericin B Liposome

2K Part D claims (CY24) · 410 beneficiaries · First FDA approval: 2025-08-06

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $3.7M

Class share

99%

of class CY24 spend

View profile →

Amphotericin B

Brand: AmBisome · 208 Part D claims (CY24) · 78 beneficiaries · First FDA approval: 1992-04-29

5 generic mfrs 658 plans require PA Discontinued